Literature DB >> 9569948

Cancer in end-stage renal disease: potential factors involved -editorial-.

S Vamvakas1, U Bahner, A Heidland.   

Abstract

Increased incidence of cancer at various sites is observed in patients with end-stage renal disease (ESRD). In particular, lymphomas and carcinomas of the kidney, prostate, liver and uterus show an enhanced prevalence in these subjects compared with the general population. A multitude of factors directly or indirectly associated with the renal disease and the treatment regimens may contribute to the increased tumor formation in these patients. Impaired function of the immune system and of DNA repair mechanisms as well as reduced antioxidant defense, accumulation of carcinogenic compounds partly due to reduced renal elimination as well as chronic infections and inflammations are found more frequently in patients with ESRD compared with the general population and may act in concert to accelerate malignant transformation and tumor formation.

Entities:  

Mesh:

Year:  1998        PMID: 9569948     DOI: 10.1159/000013314

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  40 in total

1.  The prevalence of colorectal neoplasia in patients with end-stage renal disease: a case-control study.

Authors:  Sharon Lee; Nir Wasserberg; Patrizio Petrone; Jason Rosca; Rick Selby; Adrian Ortega; Howard S Kaufman
Journal:  Int J Colorectal Dis       Date:  2007-09-13       Impact factor: 2.571

2.  Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients.

Authors:  Cécile Contin; Vincent Pitard; Yahsou Delmas; Nadège Pelletier; Thierry Defrance; Jean-François Moreau; Pierre Merville; Julie Déchanet-Merville
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

3.  Treatment strategy for bladder cancer in patients on hemodialysis: a clinical review of 28 cases.

Authors:  Yasuyuki Sato; Tsunenori Kondo; Toshio Takagi; Iizuka Junpei; Kazunari Tanabe
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

4.  CKD and risk of renal cell carcinoma: a causal association?

Authors:  Jonathan N Hofmann; Mark P Purdue
Journal:  J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 10.121

5.  Cancer risk in patients receiving renal replacement therapy: A meta-analysis of cohort studies.

Authors:  Weifeng Shang; Liu Huang; Li Li; Xiaojuan Li; Rui Zeng; Shuwang Ge; Gang Xu
Journal:  Mol Clin Oncol       Date:  2016-07-07

6.  Elevated serum soluble interleukin-2 receptor levels increase malignancy-related risk in patients on chronic hemodialysis.

Authors:  Chen XiaoHong; Shen Bo; Xiang FangFang; Guo Man; Zou JianZhou; Liu ZhongHua; Lv WenLv; Cao XueSen; Ding XiaoQiang; Zhang Boheng
Journal:  Int J Clin Oncol       Date:  2019-06-10       Impact factor: 3.402

7.  The incidence of urinary tract cancers is related to preserved diuresis: a single-center report.

Authors:  Vedran Premuzic; Marija Gamulin; Marijana Coric; Bojan Jelakovic
Journal:  Int Urol Nephrol       Date:  2017-10-16       Impact factor: 2.370

8.  The management of well-differentiated thyroid cancer with end-stage renal disease.

Authors:  Tien-Hsiang Wang; Chen-Hsen Lee; Ling-Ming Tseng; Ren-Hsieng Liu
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.633

9.  Risk factors and incidence of malignant neoplasms after kidney transplantation at a single institution in Japan.

Authors:  Kengo Horie; Tomohiro Tsuchiya; Koji Iinuma; Yuka Maekawa; Keita Nakane; Taku Kato; Kosuke Mizutani; Takuya Koie
Journal:  Clin Exp Nephrol       Date:  2019-08-01       Impact factor: 2.801

10.  Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study.

Authors:  Marina T van Leeuwen; Angela C Webster; Margaret R E McCredie; John H Stewart; Stephen P McDonald; Janaki Amin; John M Kaldor; Jeremy R Chapman; Claire M Vajdic; Andrew E Grulich
Journal:  BMJ       Date:  2010-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.